🇺🇸 FDA

Company profile · Sponsor

Eikon

Eikon Therapeutics

EIKN · NYSE biotech MILLBRAE, CA, USA
Pipeline
15
Drugs
0
Patents
4

Quick answer

Eikon (EIKN) is a biotech company. headquartered in MILLBRAE, CA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 4 patents to this profile..

Company facts

Ticker EIKN
Exchange NYSE
Company type biotech
Headquarters MILLBRAE, CA, USA
SEC CIK 0001861123

Pipeline (15)

Search pipeline →

  1. EIK1001

    Eikon

    Non Small Cell Lung Cancer (Squamous or Non Squamous)

    phase 3 small molecule active

    1 trial

  2. EIK1001

    Eikon

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  3. PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    Eikon

    Advanced Melanoma

    phase 3 small molecule active

    1 trial

  4. Association atezolizumab + BDB001 + RT

    Eikon

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  5. BDB001

    Eikon

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  6. EIK1001

    Eikon

    NSCLC

    phase 2 small molecule active

    1 trial

  7. EIK1003 5mg Tablets, PREDNISONE , ABIRATERONE , EIK1003 20mg Tablets, PACLITAXEL

    Eikon

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  8. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  9. EIK1004-001 (IMP1707-001)

    Eikon

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  10. EIK1005

    Eikon

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. EIK1005 10mg Tablets, EIK1005 50mg Tablets, PEMBROLIZUMAB , EIK1005 200mg Tablets

    Eikon

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  12. IMP1734

    Eikon

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  13. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. BDB001 (EIK1001)

    Eikon

    Tumor, Solid

    phase 1 small molecule completed

    2 trials

  15. BDB018

    Eikon

    Tumor, Solid

    phase 1 small molecule completed

    1 trial

Patents (4)

Search patents →

  1. US 12370194

    Metalloenzyme inhibitor compounds

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11938134

    Metalloenzyme inhibitor compounds

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11596585

    Composition for the prevention of microbial growth

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 6421455

    Method for detecting cancer on skin of humans and mammals and arrangement for performing the method

    Expires Mon Jul 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is Eikon?

Eikon (EIKN) is a biotech company. headquartered in MILLBRAE, CA, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 4 patents to this profile..

What pipeline programs does Eikon sponsor?

We track 15 ClinicalTrials.gov-linked programs for Eikon, including EIK1001 and 14 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Eikon company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.